Aramark バランスシートの健全性
財務の健全性 基準チェック /26
Aramarkの総株主資本は$3.3B 、総負債は$6.0Bで、負債比率は180.3%となります。総資産と総負債はそれぞれ$13.8Bと$10.5Bです。 Aramarkの EBIT は$899.9Mで、利息カバレッジ比率2.6です。現金および短期投資は$483.6Mです。
主要情報
180.29%
負債資本比率
US$6.03b
負債
| インタレスト・カバレッジ・レシオ | 2.6x |
| 現金 | US$483.58m |
| エクイティ | US$3.34b |
| 負債合計 | US$10.50b |
| 総資産 | US$13.84b |
財務の健全性に関する最新情報
Recent updates
Hyperscale Data Center Ambitions Will Strain Margins And Limit Long-Term Upside
Catalysts About Aramark Aramark provides food, facilities and hospitality services to clients across education, healthcare, business, sports, entertainment and other customer locations worldwide. What are the underlying business or industry changes driving this perspective?ARMK: Data Center Contracts And Core Execution Will Shape Future Cash Flows
The analyst price target for Aramark has been revised higher as the fair value estimate moves from $58.25 to $59.44. Analysts point to rising confidence in the Nexus data center opportunity and recent upward price target revisions across the Street as key supports for their updated view.ARMK: Data Center Builds And Nexus Platform Will Shape Future Cash Flows
Analysts increased their fair value estimate for Aramark to $58.25 from $56.63, citing a series of recent price target raises toward $65 to $70.50 that reflect growing confidence in the Nexus platform, tighter cost control through the middle of the P&L and the long-term potential of the data center services opportunity. Analyst Commentary Recent Street research on Aramark clusters around a more constructive view of the company’s growth and margin potential, particularly around the Nexus platform and the emerging data center services business.Aramark: Demand Is Strong, And Nexus Is A New Growth Driver
Summary I am upgrading Aramark to buy as commercial momentum is now translating into visible revenue and margin improvement. ARMK’s organic revenue grew 12% in Q2 2026, with broad-based strength and >98% client retention, supporting a durable growth thesis. Nexus, targeting hyperscale AI data centers, offers a new, higher-margin growth driver not yet reflected in FY2026 guidance. Valuation at ~22x NTM PE is justified by structural growth drivers, with potential upside to ~$68–$85 per share by FY28–FY29. Read the full article on Seeking AlphaAramark (ARMK) Stock Could Be 4.3% Undervalued After School Menu Update
Aramark (ARMK) stock is in focus after Aramark Student Nutrition announced updated school menus for the 2026-2027 year, emphasizing ingredient transparency, removal of several additives, and closer alignment with regulatory trends. See our latest analysis for Aramark. The updated Aramark Student Nutrition menus land at a time when momentum in Aramark stock has been building, with a 90 day share price return of 32.62% and a year to date share price return of 48.17%, while total shareholder...ARMK: Data Center Buildouts And Core Contracts Will Shape Future Cash Generation
Aramark's analyst price target has been updated from $55.25 to $56.63, reflecting analysts' focus on the company's expanding data center services and ongoing momentum in its core contracts as key factors in their revised assumptions. Analyst Commentary Recent research updates show a clear shift higher in valuation assumptions for Aramark, with multiple firms lifting their price targets into the mid to high US$50s and some reaching into the low US$60s.ARMK: Data Center Contracts And Core Markets Will Shape Future Cash Generation
The analyst price target for Aramark has been raised from $52.63 to $55.25 as analysts factor in recent Q2 upside, indications of stronger FY26 growth, new data center opportunities, and continued momentum in core end markets. Analyst Commentary Recent research updates show a cluster of higher price targets for Aramark following the latest Q2 results and guidance commentary, with many analysts pointing to earnings momentum and new contract opportunities as key drivers for their revised views.ARMK: Data Center Upside And Health Contract Will Support Future Free Cash Flow
Analysts lifted the Aramark price target by $5 to $52.63, citing solid Q2 results, expanding data center and hyperscaler multiservice opportunities, and broadly higher long term estimates across revenue, margins and future P/E assumptions. Analyst Commentary Recent research updates cluster around a common message that Aramark is executing well on Q2 priorities, with price targets moving higher on the back of solid earnings, a clearer data center opportunity and ongoing new business wins.ARMK: Organic Wins And 2026 Health Contract Will Support Future Free Cash Flow
The analyst price target for Aramark is adjusted modestly higher to $47.63 from $47.16, with analysts pointing to steadier revenue growth assumptions, a slightly higher profit margin outlook, and recent positive research highlighting organic growth and new contract wins as support for the change. Analyst Commentary Recent research around Aramark centers on organic growth trends, contract wins and how these factors feed into valuation.ARMK: Organic Wins And 2026 Health Contract Will Support Future Free Cash Flow
Aramark's analyst price target has inched higher, with a modest fair value adjustment to about $47.16 as analysts highlight stronger than expected organic growth trends, a new RWJ Barnabas Health contract scheduled to ramp up in 2026, and generally constructive sector views as key supports. Analyst Commentary Bullish analysts are generally constructive on Aramark, pointing to recent price target increases and renewed coverage with higher fair value estimates.ARMK: New Contracts And Buybacks Will Support Future Free Cash Flow
Analysts have raised the implied fair value for Aramark by about $0.47 to $47.09, reflecting updated assumptions around revenue growth, profitability and future P/E in the context of a recent wave of higher $50 price targets across research reports. Analyst Commentary Recent research updates cluster around a US$50 price target, with several firms lifting their views in quick succession.ARMK: Contract Wins And Buybacks Will Support Higher FY26 Cash Generation
Narrative Update Analysts have lifted their average price target on Aramark by about $3 to $50, citing stronger than expected organic growth and increased visibility from a new RWJ Barnabas Health contract, as well as broader optimism regarding revenue, EPS and free cash flow trends into 2026. Analyst Commentary Recent Street research on Aramark centers on higher price targets and fresh coverage, with most of the discussion tied to organic growth trends, contract wins and expectations for earnings and cash flow through 2026.ARMK: Contract Wins And Buybacks Will Support Stronger FY26 Earnings Delivery
Analysts have lifted their average Aramark price target from about $44.60 to roughly $46.63. The updated views factor in recent organic growth trends and expectations for future contract contributions and earnings power.ARMK: Contract Timing Delays Will Support Stronger FY26 Earnings Delivery
Narrative Update on Aramark Analysts have trimmed their Aramark price target to US$44 from US$49, citing a shift in expected revenue timing as client driven delays in new contract starts across Corrections, Workplace Experience, and Healthcare push more of the projected contribution into FY26. They continue to model a similar long term P/E and margin profile.ARMK: Contract Timing Delays Will Create FY26 Margin Upside Scenario
Analysts recently trimmed their Aramark price target to $44 from $49, pointing to what they describe as strong underlying business momentum, but also to client driven timing delays on new contract starts that are expected to shift some revenue and margin impact into FY26. Analyst Commentary Bullish Takeaways Bullish analysts see the lower US$44 price target as reflecting updated timing rather than a change in their view of Aramark’s underlying business momentum.Is Aramark (NYSE:ARMK) Worth US$38.0 Based On Its Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Aramark fair value estimate is US$30.02 Current share price of...ARMK: Delayed Contract Ramps Will Drive Stronger Earnings Setup In Fiscal 2026
Analysts have modestly reduced their price target on Aramark to approximately $44 from about $49, citing strong underlying business momentum but near term revenue and earnings pressure from client driven timing delays in new contract starts, which are now expected to shift more meaningfully into FY26. Analyst Commentary Bullish Takeaways Bullish analysts highlight that underlying business momentum remains solid across key operating segments, supporting confidence in the company’s long term growth trajectory despite near term volatility.ARMK: Delayed Contract Starts Will Support Stronger Earnings Momentum In Fiscal 2026
Analysts have trimmed their price target on Aramark to $44 from $49, reflecting expectations for strong underlying momentum but a near term zig zag in revenue and margins as client driven contract start delays shift more growth into FY26. Analyst Commentary Street research indicates that the recent price target reduction reflects adjustments to the timing of expected growth rather than a reset of the long term thesis.ARMK: Delayed Contract Starts Will Shift Earnings Momentum Toward Fiscal 2026
Analysts have modestly raised their Aramark price target to approximately $44.60 per share from about $44.43, citing strong underlying business momentum despite near term revenue and earnings pressure from client driven delays in new contract starts, which are now expected to shift growth into FY26. Analyst Commentary Recent Street research highlights a mixed, but generally constructive, view on Aramark, with analysts fine tuning their expectations to reflect both the strength of the core business and the impact of timing related revenue shifts.Earnings Miss: Aramark Missed EPS By 19% And Analysts Are Revising Their Forecasts
Aramark ( NYSE:ARMK ) shareholders are probably feeling a little disappointed, since its shares fell 4.6% to US$36.73...ARMK: Delayed Contract Starts Will Drive Revenue Expansion Beyond Fiscal 2025
Aramark's analyst price target has been revised downward from $45.10 to $44.43, as analysts factor in strong underlying business momentum while adjusting for delays in revenue and earnings due to client-driven timing in new contract starts. Analyst Commentary Analyst perspectives on Aramark reflect a mix of optimism about core business trends and caution around near-term uncertainty driven by client timing.What Is Aramark's (NYSE:ARMK) Share Price Doing?
Aramark ( NYSE:ARMK ) saw significant share price movement during recent months on the NYSE, rising to highs of...Sports, Education And Healthcare Wins Will Expand Global Reach
Aramark’s fair value estimate was slightly reduced as a result of a deteriorating net profit margin and an increased future P/E, indicating weaker profitability and pricier valuation. What's in the News Aramark expanded its presence in NCAA collegiate sports by delivering customized hospitality experiences at over 30 football stadiums and secured new partnerships with Arizona State University and the University of Nebraska.Aramark Is A 'BUY', But With Some Details (Rating Upgrade)
Summary I initially invested in Aramark, saw a 50%+ gain, then switched to Sodexo, which has shown potential for further growth. Despite Aramark's recent 14% decline, I see a long-term investment opportunity, especially with Sodexo's potential acquisition interest. Aramark's strong performance, revenue growth, and improved margins make it a compelling buy, with an updated price target of $40/share. While Aramark is a "BUY," Sodexo remains a superior choice due to better credit rating, yield, and overall fundamentals. Read the full article on Seeking AlphaAramark: Rating Downgrade To Hold As I See Risk To The Company Meeting FY25 Guidance
Summary I downgraded ARMK from buy to hold due to 1Q25 performance and risks of missing FY25 guidance. Weak US organic growth and onboarding delays in Education and Healthcare segments pose significant risks to achieving FY25 targets. Strong international growth is promising but may not offset US weaknesses and potential FX headwinds. ARMK's valuation could drop significantly if growth slows, with potential de-rating to low teens forward earnings multiple. Read the full article on Seeking AlphaAramark: Robust FY25 Outlook
Summary I reiterate a buy rating for ARMK due to its robust FY25 outlook, driven by organic growth and a strengthened balance sheet. Aramark's 4Q24 earnings were in line with expectations, with revenue growth driven by organic means and strong pipeline momentum. The launch of Avendra, ARMK's global GPO, is expected to enhance margins by leveraging scale for better purchasing deals. ARMK's improved balance sheet allows for increased shareholder returns through dividends and a $500 million share buyback program. Read the full article on Seeking Alpha財務状況分析
短期負債: ARMKの 短期資産 ( $3.7B ) が 短期負債 ( $3.1B ) を超えています。
長期負債: ARMKの短期資産 ( $3.7B ) は 長期負債 ( $7.4B ) をカバーしていません。
デット・ツー・エクイティの歴史と分析
負債レベル: ARMKの 純負債対資本比率 ( 165.8% ) は 高い と見なされます。
負債の削減: ARMKの負債対資本比率は、過去 5 年間で308.3%から180.3%に減少しました。
債務返済能力: ARMKの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 14.4% )。
インタレストカバレッジ: ARMKの負債に対する 利息支払い は EBIT ( 2.6 x coverage) によって 十分にカバーされていません。
貸借対照表
健全な企業の発掘
企業分析と財務データの現状
| データ | 最終更新日(UTC時間) |
|---|---|
| 企業分析 | 2026/07/31 22:41 |
| 終値 | 2026/07/31 00:00 |
| 収益 | 2026/04/03 |
| 年間収益 | 2025/10/03 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Aramark 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23
| アナリスト | 機関 |
|---|---|
| Andrew Wittmann | Baird |
| Manav Patnaik | Barclays |
| Stuart Gordon | Berenberg |